Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk (SHORT RUN AF)

The primary objective of the Short Run AF study is to evaluate the efficacy and safety of long term anticoagulation with rivaroxaban against standard of care (SOC) in patients with ESVEA and CHA2DS2VASC score ≥3 on the incidence of ischemic stroke and peripheral embolism after 2 years follow-up and the occurrence of major bleeding events.

The primary efficacy endpoint is the first ischemic stroke or peripheral embolism detected clinically and on systematic cerebral MRIs in a time-to-event analysis.

The primary safety outcome is major bleeding at any site in the body according to the criteria of the International Society of Thrombosis and Hemostasis (ISTH)(23-25).

Study Overview

• Status: Not yet recruiting
• Conditions: Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
• Intervention / Treatment: Drug: Rivaroxaban group

Detailed Description

Patients with atrial fibrillation (AF) (> 30 consecutive seconds of arrhythmia) and high risk embolism meaning CHA2DS2VASC score ≥2 are candidate for long term oral anticoagulation. In addition, patients with excessive supraventricular ectopies or short atrial runs (ESVEA) but no documented AF are also at higher risk of systemic embolism compared to normal population. ESVEA is a frequent clinical situation observed approximately in up to 15% on systematic 24-hour Holter ECG in patients over 65 years old with cardiovascular risk factors. In addition, it is associated with a higher risk of peripheral arterial thromboembolism. However, it remains unclear if this former population could benefit from long-term oral anticoagulation.

To date no other studies have evaluated the effect of anticoagulation for patients with excessive atrial ectopies or short atrial runs. Also, to our knowledge, no study evaluating this problematic is ongoing. This population is actually not treated but in real clinical practice, patients with high CHA2DS2VASC score presenting with ESVEA could be candidate for oral anticoagulation. If it is demonstrated that patients with ESVEA and CHA2DS2VASC score ≥ 3 could benefit from oral anticoagulation and particularly new oral anticoagulants, it would change the everyday practice of cardiologist or gerontologist.

Our hypothesis is that long term anticoagulation with rivaroxaban could reduce drastically (50%, comparable with its effect during AF) the incidence of stroke or other thromboembolism events compared to standard of care (SOC), with a possible but moderate increased risk of bleeding compared to SOC that should remain acceptable compared to the reduction of stroke (net clinical benefit).

In this study, the study also attempt to describe the clinical course of patients with ESVEA in terms of global cardiovascular events, occurrence of documented atrial fibrillation or cognitive decline with an everyday practice follow-up.

• Study Type: Interventional
• Enrollment (Anticipated): 550
• Phase: Phase 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients ≥ 65 years old
• Diagnosis of excessive supraventricular ectopy activity defined as ≥ 1% PAC / 24 h or any atrial runs ≥ 20 PACs on a 24-hour Holter ECG monitoring (the indication for the Holter will be let at the discretion of the doctor according to international guidelines indication)
• High risk embolism defined by a CHA2DS2VASC score ≥ 3
• Written consent from patient
• Patients able to attend consultations and Cerebral MRI at baseline and 24 months at the participating centre.
• Ability to understand and comply with the study protocol
• Affiliation of social security regime

Exclusion Criteria:

• According to the SmPC, any contraindication to Rivaroxaban (particularly patients with ongoing major bleeding, vascular complication, prior haemorrhagic stroke or over recent stroke) or one of its excipients.
• Inability to perform cerebral MRI
• Life expectancy <24 months
• History of major hemorrhage after taking Rivaroxaban
• Documented atrial fibrillation or any other indication for oral anticoagulation
• Patients with previous documented AF
• Valvular congenital heart disease
• Anticoagulant agents in the month prior to the inclusion visit
• Acute coronary syndrome, coronary revascularization (percutaneous coronary intervention or coronary artery bypass surgery) or in the past 30 days
• Requires long-term antiplatelet therapy other than aspirin (i.e., patient requires any platelet aggregation inhibitor in addition to study treatment, in particular, the combination of two platelet aggregation inhibitors)
• Ongoing need for strong inhibitors of both CYP3A4 and P-glycoprotein (e.g., ketoconazole, itraconazole, ritonavir or clarithromycin)
• Ongoing need for strong inducers of both CYP3A4 and P-glycoprotein (e.g., rifampin, carbamazepine, phenytoin)
• Participants considered by the investigator to be unsuitable for the study for any of the following reasons:Patient refuse the treatment with rivaroxaban or anticipated to have poor compliance on study drug treatment or Unwilling to attend study follow-up visits
• Cancer or other life threatening conditions
• Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days

• Conditions associated with an increased risk of bleeding:

  1. Major surgery within the previous month
  2. Planned surgery or intervention within the next 3 months
  3. History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra-articular bleeding
  4. Gastrointestinal hemorrhage within the past year
  5. Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days
  6. Hemorrhagic disorder or bleeding diathesis
  7. Need for anticoagulant treatment of disorders other than atrial fibrillation
  8. Fibrinolytic agents within 48 hours of study entry
  9. Uncontrolled hypertension (systolic blood pressure greater than 180 mm Hg and/or diastolic blood pressure greater than 100 mm Hg)
  10. Recent malignancy or radiation therapy (within 6 months) and not expected to survive 3 years
• Severe renal impairment (estimated creatinine clearance <30 mL/min or less)
• Active infective endocarditis
• Active liver disease, including but not limited to, associated or not with coagulopathy and a clinically significant risk of bleeding, including cirrhotic patients with a Child Pugh class B or C score.
• Persistent ALT, AST, Alk Phos greater than twice the upper limit of the normal range
• Known active hepatitis C (positive HCV RNA)
• Known active hepatitis B (HBs antigen +, anti HBc IgM +)
• Known active hepatitis A
• Anemia (hemoglobin level less than 110 g/L) or thrombocytopenia (platelet count less than 150 X 109/L)
• Patients who have received an investigational drug in the past 30 days
• Patients considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)
• Patient with cardiac prosthetic devices : Reveal, pace-maker, automatic implantable defibrillator
• Participation in another interventional clinical trial
• Patient on AME (state medical aid)
• Persons under psychiatric care
• Adults subject to a legal protection measure (guardianship, curatorship and safeguard of justice)Patients deprived of their liberty by a judicial or administrative decision

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: experimental group; Patients in the Rivaroxaban group will receive Rivaroxaban at the dose of 15 mg once daily ((or 10 mg if renal insufficiency) during 2 years.	Drug: Rivaroxaban group; Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
No Intervention: group control; Patients in the control group will be followed according to the standard of care (SOC) chosen by the investigator during 2 years. Additions or changes to SOC are allowed during the patient participation in the study based on patient status and evolution (with the exception of the use of anticoagulant therapy).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
incidence of first ischemic stroke or peripheral embolism	The primary efficacy endpoint is the first ischemic stroke or peripheral embolism detected clinically and on systematic cerebral MRIs in a time-to-event analysis.	during 28 months follow-up
incidence of major bleeding at any site in the body	The primary safety outcome is major bleeding at any site in the body according to the criteria of the International Society of Thrombosis and Hemostasis (ISTH)(23-25).	2-year follow-up.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the incidence of documented atrial fibrillation	the incidence of documented atrial fibrillation diagnosed from patient symptoms or systematic 24 hours ECG Holter performed at 2-year follow-up.	2-year follow-up.

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Anticipated): April 5, 2023
• Primary Completion (Anticipated): April 5, 2027
• Study Completion (Anticipated): April 5, 2027

Study Registration Dates

• First Submitted: August 2, 2022
• First Submitted That Met QC Criteria: August 2, 2022
• First Posted (Actual): August 4, 2022

Study Record Updates

• Last Update Posted (Actual): March 28, 2023
• Last Update Submitted That Met QC Criteria: March 24, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: atrial fibrillation; embolism; RIVAROXABAN; short atrial runs (ESVEA)
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Embolism and Thrombosis; Embolism; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protease Inhibitors; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Anticoagulants; Rivaroxaban
• Other Study ID Numbers: APHP200002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No